Published in Strahlenther Onkol on July 01, 2006
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer (2011) 1.13
Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer (2007) 1.00
Association of telomerase activity with radio- and chemosensitivity of neuroblastomas. Radiat Oncol (2010) 0.90
Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study. Int Arch Med (2010) 0.82
Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys (2014) 0.82
Intraoperative radiation therapy for advanced neuroblastoma: the problem of securing the IORT field. Pediatr Surg Int (2007) 0.80
Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2010) 0.80
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer (2015) 0.75
Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. J Clin Oncol (2016) 0.75
Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China. J Cancer Res Clin Oncol (2017) 0.75
Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. Int J Radiat Oncol Biol Phys (2016) 0.75
Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC Cancer (2017) 0.75
Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015. Paediatr Drugs (2017) 0.75
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35
Neuroblastoma screening at one year of age. N Engl J Med (2002) 3.93
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol (2005) 2.75
Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res (2004) 2.49
Direct visual observation of thermal capillary waves. Science (2004) 2.36
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology (2011) 2.35
Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol (2003) 2.22
Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res (2004) 1.96
Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol (2008) 1.91
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 1.79
Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res (2009) 1.71
Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol (2008) 1.64
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol (2004) 1.64
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clin Chem (2009) 1.62
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol (2011) 1.62
Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg (2005) 1.60
Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol (2010) 1.43
Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer (2006) 1.38
Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol (2012) 1.38
Endovascular gamma irradiation of femoropopliteal de novo stenoses immediately after PTA: interim results of prospective randomized controlled trial. Radiology (2002) 1.38
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol (2012) 1.37
Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer (2008) 1.36
Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol (2008) 1.33
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics (2004) 1.33
Current diagnosis and treatment of spondylodiscitis. Dtsch Arztebl Int (2008) 1.30
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res (2004) 1.30
Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer (2010) 1.30
Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT single photon emission computed tomography. Mov Disord (2011) 1.29
'Show me the money': financial incentives increase chlamydia screening rates among tertiary students: a pilot study. Sex Health (2010) 1.28
Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol (2015) 1.26
Treatment options in childhood pontine gliomas. J Neurooncol (2006) 1.26
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
Recent progress in understanding Alzheimer's β-amyloid structures. Trends Biochem Sci (2011) 1.24
Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn (2005) 1.23
Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet Oncol (2005) 1.20
Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas. J Urol (2004) 1.16
Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res (2003) 1.15
The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer (2008) 1.15
Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother (2004) 1.15
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer (2010) 1.14
Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer (2011) 1.13
Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Clin Cancer Res (2010) 1.12
Quality control in urinary stone analysis: results of 44 ring trials (1980-2001). Clin Chem Lab Med (2005) 1.07
Methods and implementation of a central biosample and data management in a three-centre clinical study. Comput Methods Programs Biomed (2008) 1.07
The potassium channel subunit Kvbeta3 interacts with pannexin 1 and attenuates its sensitivity to changes in redox potentials. FEBS J (2009) 1.07
Critical Assessment Is Missing. Dtsch Arztebl Int (2017) 1.07
Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin Cancer Res (2006) 1.07
Heterogeneity of the MYCN oncogene in neuroblastoma. Clin Cancer Res (2009) 1.06
Factors affecting infection after calcaneal fracture fixation. Injury (2009) 1.05
Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res (2006) 1.05
Surface-binding autoantibodies to cerebellar neurons in opsoclonus syndrome. Ann Neurol (2005) 1.05
PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol (2008) 1.05
Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Lett (2006) 1.05
Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res (2006) 1.04
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res (2011) 1.04
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett (2005) 1.04
Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer (2007) 1.03
An asymmetric dimer as the basic subunit in Alzheimer's disease amyloid β fibrils. Angew Chem Int Ed Engl (2012) 1.03
[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg (2009) 1.02
Parkinson subtypes progress differently in clinical course and imaging pattern. PLoS One (2012) 1.02
A three-gene expression signature model for risk stratification of patients with neuroblastoma. Clin Cancer Res (2012) 1.02
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Mol Oncol (2008) 1.01
GABA receptor rho subunit expression in the developing rat brain. Brain Res Dev Brain Res (2005) 1.01
Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun (2010) 1.01
Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett (2005) 1.00
New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol (2004) 1.00
Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. Int J Cancer (2012) 0.99
White matter hyperintensities in affected and unaffected late teenage and early adulthood offspring of bipolar parents: a two-center high-risk study. J Psychiatr Res (2010) 0.99
Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol (2013) 0.99
Diagnostic work-up and outcome of cervical metastases from an unknown primary. Acta Otolaryngol (2006) 0.98
Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol (2013) 0.98
Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature. Radiat Oncol (2013) 0.97